Literature DB >> 22248356

A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A.

Mathew P Martin1, Jin-Yi Zhu, Harshani R Lawrence, Roberta Pireddu, Yunting Luo, Riazul Alam, Sevil Ozcan, Said M Sebti, Nicholas J Lawrence, Ernst Schönbrunn.   

Abstract

Most protein kinases share a DFG (Asp-Phe-Gly) motif in the ATP site that can assume two distinct conformations, the active DFG-in and the inactive DFG-out states. Small molecule inhibitors able to induce the DFG-out state have received considerable attention in kinase drug discovery. Using a typical DFG-in inhibitor scaffold of Aurora A, a kinase involved in the regulation of cell division, we found that halogen and nitrile substituents directed at the N-terminally flanking residue Ala273 induced global conformational changes in the enzyme, leading to DFG-out inhibitors that are among the most potent Aurora A inhibitors reported to date. The data suggest an unprecedented mechanism of action, in which induced-dipole forces along the Ala273 side chain alter the charge distribution of the DFG backbone, allowing the DFG to unwind. As the ADFG sequence and three-dimensional structure is highly conserved, DFG-out inhibitors of other kinases may be designed by specifically targeting the flanking alanine residue with electric dipoles.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22248356      PMCID: PMC4429595          DOI: 10.1021/cb200508b

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  45 in total

Review 1.  Protein electrostatics: a review of the equations and methods used to model electrostatic equations in biomolecules--applications in biotechnology.

Authors:  Maria Teresa Neves-Petersen; Steffen B Petersen
Journal:  Biotechnol Annu Rev       Date:  2003

2.  Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics.

Authors:  Federico Filomia; Francesca De Rienzo; M Cristina Menziani
Journal:  Bioorg Med Chem       Date:  2010-07-29       Impact factor: 3.641

3.  Orbital signatures of methyl in L-alanine.

Authors:  Chantal T Falzon; Feng Wang; Wenning Pang
Journal:  J Phys Chem B       Date:  2006-05-18       Impact factor: 2.991

4.  A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

Authors:  Güllü Görgün; Elisabetta Calabrese; Teru Hideshima; Jeffrey Ecsedy; Giulia Perrone; Mala Mani; Hiroshi Ikeda; Giada Bianchi; Yiguo Hu; Diana Cirstea; Loredana Santo; Yu-Tzu Tai; Sabikun Nahar; Mei Zheng; Madhavi Bandi; Ruben D Carrasco; Noopur Raje; Nikhil Munshi; Paul Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-09       Impact factor: 22.113

5.  Halogen bonding--a novel interaction for rational drug design?

Authors:  Yunxiang Lu; Ting Shi; Yong Wang; Huaiyu Yang; Xiuhua Yan; Xiaoming Luo; Hualiang Jiang; Weiliang Zhu
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

6.  Halogen bonding in supramolecular chemistry.

Authors:  Pierangelo Metrangolo; Franck Meyer; Tullio Pilati; Giuseppe Resnati; Giancarlo Terraneo
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

7.  Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.

Authors:  Yongmun Choi; Farisa Syeda; John R Walker; Patrick J Finerty; Dominic Cuerrier; Amy Wojciechowski; Qingsong Liu; Sirano Dhe-Paganon; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2009-05-13       Impact factor: 2.823

8.  The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.

Authors:  Justin Dietrich; Christopher Hulme; Laurence H Hurley
Journal:  Bioorg Med Chem       Date:  2010-06-04       Impact factor: 3.641

9.  X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors.

Authors:  Andreas Kuglstatter; Manjiri Ghate; Stan Tsing; Armando G Villaseñor; David Shaw; Jim W Barnett; Michelle F Browner
Journal:  Bioorg Med Chem Lett       Date:  2010-07-23       Impact factor: 2.823

10.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04
View more
  23 in total

1.  Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Authors:  Matthew P Martin; Yunting Luo; Roberta Pireddu; Hua Yang; Harsukh Gevariya; Harshani R Lawrence; Sevil Ozcan; Jin-Yi Zhu; Robert Kendig; Mercedes Rodriguez; Roy Elias; Jin Q Cheng; Saïd M Sebti; Ernst Schonbrunn; Nicholas J Lawrence
Journal:  J Med Chem       Date:  2012-08-30       Impact factor: 7.446

2.  Design, synthesis, and biological evaluation of polyphenols with 4,6-diphenylpyrimidin-2-amine derivatives for inhibition of Aurora kinase A.

Authors:  Young Han Lee; Jihyun Park; Seunghyun Ahn; Youngshim Lee; Junho Lee; Soon Young Shin; Dongsoo Koh; Yoongho Lim
Journal:  Daru       Date:  2019-06-01       Impact factor: 3.117

3.  Sequence determinants of a specific inactive protein kinase conformation.

Authors:  Sanjay B Hari; Ethan A Merritt; Dustin J Maly
Journal:  Chem Biol       Date:  2013-06-20

4.  A novel approach to the discovery of small-molecule ligands of CDK2.

Authors:  Mathew P Martin; Riazul Alam; Stephane Betzi; Donna J Ingles; Jin-Yi Zhu; Ernst Schönbrunn
Journal:  Chembiochem       Date:  2012-08-14       Impact factor: 3.164

5.  Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.

Authors:  Harshani R Lawrence; Kiran Mahajan; Yunting Luo; Daniel Zhang; Nathan Tindall; Miles Huseyin; Harsukh Gevariya; Sakib Kazi; Sevil Ozcan; Nupam P Mahajan; Nicholas J Lawrence
Journal:  J Med Chem       Date:  2015-03-17       Impact factor: 7.446

6.  A water-mediated allosteric network governs activation of Aurora kinase A.

Authors:  Soreen Cyphers; Emily F Ruff; Julie M Behr; John D Chodera; Nicholas M Levinson
Journal:  Nat Chem Biol       Date:  2017-02-06       Impact factor: 15.040

7.  Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.

Authors:  Natalia J Sumi; Claudia Ctortecka; Qianqian Hu; Annamarie T Bryant; Bin Fang; Lily L Remsing Rix; Muhammad Ayaz; Fumi Kinose; Eric A Welsh; Steven A Eschrich; Harshani R Lawrence; John M Koomen; Eric B Haura; Uwe Rix
Journal:  Cell Chem Biol       Date:  2019-06-27       Impact factor: 8.116

8.  Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules.

Authors:  Jiun-Ming Wu; Chiung-Tong Chen; Mohane Selvaraj Coumar; Wen-Hsin Lin; Zi-Jie Chen; John T-A Hsu; Yi-Hui Peng; Hui-Yi Shiao; Wen-Hsing Lin; Chang-Ying Chu; Jian-Sung Wu; Chih-Tsung Lin; Ching-Ping Chen; Ching-Cheng Hsueh; Kai-Yen Chang; Li-Pin Kao; Chi-Ying F Huang; Yu-Sheng Chao; Su-Ying Wu; Hsing-Pang Hsieh; Ya-Hui Chi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

9.  Drugging MYCN through an allosteric transition in Aurora kinase A.

Authors:  William Clay Gustafson; Justin Gabriel Meyerowitz; Erin A Nekritz; Justin Chen; Cyril Benes; Elise Charron; Erin F Simonds; Robert Seeger; Katherine K Matthay; Nicholas T Hertz; Martin Eilers; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2014-08-28       Impact factor: 31.743

10.  Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.

Authors:  Ernst Schonbrunn; Stephane Betzi; Riazul Alam; Mathew P Martin; Andreas Becker; Huijong Han; Rawle Francis; Ramappa Chakrasali; Sudhakar Jakkaraj; Aslamuzzaman Kazi; Said M Sebti; Christopher L Cubitt; Anthony W Gebhard; Lori A Hazlehurst; Joseph S Tash; Gunda I Georg
Journal:  J Med Chem       Date:  2013-05-06       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.